Home›The Library›Is BPC-157 legal?
Is BPC-157 legal in 2026?
No — not for the injectable, human-use way it's actually sold. A 2026 regulatory change removed it from an FDA restricted list, and that change is widely being misreported as legalisation. It isn't.
On this page
In brief
Should you care? Yes — this is one of the most searched, most confused legal questions in the category right now, and a lot of vendors are actively using the confusion to sell. Removal from a restricted list is not approval, and it is not legalisation.The short version
- April 2026: BPC-157 removed from FDA Category 2, alongside 11 other peptides.
- What that means: FDA no longer flags it for a specific safety concern — nothing more.
- What it does not mean: it is not an approved drug, and it is not a lawful supplement ingredient.
What actually changed in 2026
On 27 February 2026, on The Joe Rogan Experience (episode 2461), HHS Secretary Robert F. Kennedy Jr said that roughly 14 of the peptides then on the FDA’s Category 2 restricted compounding list — reported variously as a list of 17 or 19, depending on the source — would move back to Category 1, BPC-157 among them.1 In mid-to-late April 2026, the FDA formally removed 12 named peptides, including BPC-157, from Category 2. On 23–24 July 2026, the agency’s Pharmacy Compounding Advisory Committee reviewed seven of the removed peptides over two days and, by the end of the second day, had recommended six — BPC-157, KPV, TB-500, MOTS-c, Semax and Epitalon — for Category 1 status, rejecting one (DSIP).2
What Category 1 would mean, if it happens
Category 1 is the status that makes a bulk substance eligible for compounding by a licensed pharmacy under section 503A, on a valid physician’s prescription. If BPC-157 reaches Category 1, the practical effect is a prescription channel through a licensed compounding pharmacy — not an over-the-counter product, and not a lawful basis for the RUO vials currently sold online.
An advisory recommendation is not an agency action
The Pharmacy Compounding Advisory Committee’s July 2026 recommendation is exactly that — a recommendation. It is not the same as the FDA placing BPC-157 in Category 1, and as of this page’s last review, that formal step has not happened.
What hasn’t changed
- BPC-157 remains an unapproved drug. Removal from Category 2 changes a compounding-eligibility flag; it does not constitute drug approval.
- It is not a lawful dietary supplement ingredient. Selling it as a supplement remains outside the law regardless of the Category 2 change.
- Selling it as an injectable "research chemical" to consumers remains the same legal exposure it always was — see why RUO labelling doesn’t change this.
Where the confusion comes from
Headlines and vendor marketing have widely compressed "removed from a restricted list" into "legalised." The two are not the same, and the gap between them is precisely where a buyer can end up holding a legally risky product while genuinely believing, in good faith, that a recent news cycle made it fine. We’d rather spell out the actual mechanism than let that compression stand.
References
- Widely reported at the time, including by NPR, CBS News and The Washington Post — coverage of Secretary Kennedy's 27 February 2026 podcast remarks and the FDA's subsequent mid-to-late April 2026 removal of 12 named peptides from Category 2. We have not been able to link directly to a single FDA.gov press release stating every figure in one place; the specific list size (17 vs 19) varies between trackers, which is why we've flagged that uncertainty in the text rather than picking one number and presenting it as settled.
- Coverage of the Pharmacy Compounding Advisory Committee's 23–24 July 2026 meeting, including day-two tallies reported by the American Journal of Managed Care and law-firm regulatory trackers (Holland & Knight, Frier Levitt); same-day wire coverage on 23 July captured only the first day's partial vote count, which is why some outlets reported four recommended peptides rather than the fuller six-peptide, two-day total used here.